Nipah Virus in depth.

Overview

Nipah virus disease is a rare but highly lethal zoonotic infection affecting the brain and respiratory system. Caused by Nipah virus (NiV, Paramyxoviridae), it spreads through contact with infected bats, pigs, or people, or through consumption of raw date palm sap contaminated with bat secretions. Key symptoms: fever, headache, drowsiness, disorientation, and acute encephalitis. The case fatality rate ranges from 40% to 75% across documented outbreaks.

Nipah is listed as a WHO Priority Pathogen and a CEPI R&D Blueprint priority — a disease requiring urgent vaccine and treatment development due to its epidemic and pandemic potential. The case fatality rate ranges from 40% to 75% depending on the outbreak setting and healthcare capacity. The virus can spread from bats to humans, from pigs to humans, and — critically — from human to human, which distinguishes it from many other zoonoses and raises pandemic concerns.

Since 1998, approximately 700 human Nipah cases have been recorded globally, predominantly in Bangladesh and India (particularly Kerala state). While each individual outbreak is relatively small (typically 10–100 cases), Nipah's high lethality, human-to-human transmissibility, neurological severity, and lack of approved countermeasures make it one of the most feared emerging infectious diseases in global health security discussions.

History & Origin

The 1998–1999 Malaysia outbreak involved 265 cases and 105 deaths primarily among pig farmers in Perak state. The virus spread to Singapore via imported pigs, causing 11 cases with 1 death. Control required the culling of approximately 1 million pigs. Nipah virus was isolated and characterized in 1999 by researchers from the University of Malaysia.

Bangladesh has since experienced almost annual Nipah outbreaks (2001–present), linked predominantly to consumption of raw date palm sap contaminated with infected bat urine or saliva. India (West Bengal, Kerala) has had several outbreaks. The 2018 Kerala outbreak (19 cases, 17 deaths — 89% CFR) and the 2021 Kerala outbreak (1 confirmed death) demonstrated Nipah's ongoing threat in South Asia. The 2023 Kerala outbreak (6 confirmed cases, 2 deaths) showed both the persistent threat and India's improving outbreak response capability.

Transmission

• Fruit bat to human: Consuming raw date palm sap collected in open containers that bats have accessed overnight (Bangladesh/India model). Consuming fruit partially eaten by infected bats. Direct contact with bat droppings or secretions.
• Pig to human (Malaysia/Singapore model): Direct contact with infected pigs or their respiratory secretions. Large-scale pig farming operations facilitated amplification.
• Human to human: Direct contact with body fluids (blood, respiratory secretions, urine) of infected persons. Healthcare workers without adequate PPE are at high risk. R₀ estimated at 0.3–0.5 in community settings; higher in hospital settings without infection control.
• Fomites: Limited evidence for environmental surface transmission.

Not efficiently airborne under typical conditions — though aerosol-generating procedures (intubation, bronchoscopy) in healthcare settings require airborne precautions due to respiratory secretions.

Symptom Timeline

Incubation: 4–14 days (up to 45 days in some documented cases).

Diagnosis

• RT-PCR: Detection of NiV RNA in throat swab, CSF, urine, or blood. Requires BSL-4 facilities for culture; PCR can be performed at BSL-3 with appropriate inactivation protocols.
• ELISA serology: IgM/IgG detection; IgM appears early in infection; useful for outbreak investigation.
• Neutralisation assay: Gold standard for serology; requires BSL-4 facility.
• MRI brain: Characteristic small, disseminated white matter lesions in the brainstem, periventricular regions, and cortex. Diffusion-weighted imaging (DWI) most sensitive for early Nipah encephalitis.
• CSF analysis: Pleocytosis (elevated white cells); elevated protein; may be normal early. CSF PCR for NiV RNA.
• Epidemiological link: History of exposure to bats, bat products, raw date palm sap, pigs, or contact with a confirmed case is critical for clinical suspicion in non-endemic settings.

Treatment

No specific antiviral treatment is currently recommended in WHO guidance for Nipah virus disease. Management is intensive supportive care.

• Intensive supportive care: Airway management, mechanical ventilation for respiratory failure; seizure control (benzodiazepines, phenobarbital); management of cerebral oedema (mannitol, dexamethasone); fluid and electrolyte management.
• Ribavirin: Used compassionately in several outbreaks (Malaysia 1999, India 2018). Retrospective data from Malaysia suggested possible mortality reduction; prospective evidence lacking. WHO advises it may be used compassionately pending better evidence.
• Monoclonal antibody m102.4 (HENIPAAB): Humanised monoclonal antibody targeting the Henipavirus G protein. Protected animals in challenge studies. Used in compassionate cases in Australia (Hendra) and Bangladesh (Nipah). Efficacy in humans unconfirmed by controlled trial.
• Favipiravir, remdesivir: Being studied in animal models; no human trial data available.
• Infection control: Strict contact and droplet precautions (plus airborne for aerosol-generating procedures); full PPE for all healthcare workers; single-room negative-pressure isolation where available.

Prevention — No Approved Vaccine

• No licensed vaccine exists for Nipah virus as of 2025. Several candidates are in early clinical trials: mRNA vaccines, subunit vaccines targeting the G protein and F protein.
• CEPI-funded development: Multiple vaccines in Phase I/II trials. An Indian candidate vaccine (based on recombinant Henipavirus G glycoprotein) entered human trials in 2023.
• Preventing bat-to-human transmission: Cover date palm sap collection pots overnight; avoid consuming raw sap; do not eat fruit partially eaten by bats; avoid direct contact with bats. These interventions are highly effective and have been shown to reduce outbreak incidence in Bangladesh.
• Preventing human-to-human transmission: Full PPE (gown, gloves, N95, face shield) for healthcare workers; strict hand hygiene; isolate suspected cases immediately; contact tracing of all individuals with exposure to a confirmed case.
• Community education: Awareness about date palm sap preparation and bat exposure is the most impactful prevention measure in endemic Bangladesh.

Global Impact & Pandemic Risk

Nipah's total human case count (~700) is small compared to most infectious diseases, but its characteristics make it a priority pandemic threat: high lethality (40–75% CFR), human-to-human transmission capability, wide bat reservoir distribution across South and Southeast Asia, potential for exponential spread if R₀ exceeds 1, and complete absence of approved vaccines or treatments.

The 2018 Kerala outbreak illustrated both the danger and the response challenge: it caused significant fear and economic disruption far exceeding the number of cases, strained Kerala's health system, and required deployment of national and international resources. The 2021 and 2023 Kerala outbreaks demonstrated improving outbreak detection and response capabilities in India, including rapid contact tracing, isolation, and PCR testing.

Nipah remains a centrepiece of global health security pandemic preparedness discussions. The WHO R&D Blueprint, CEPI, and national health agencies prioritize Nipah vaccine and therapeutic development as a critical unmet need. Climate change and deforestation may alter bat migration patterns and human-bat contact dynamics in ways that increase future spillover risk.

History of Nipah Outbreaks

Nipah virus (NiV) was first identified in 1998–1999 during an outbreak in Malaysia and Singapore affecting pig farmers and slaughterhouse workers. The Malaysian outbreak (265 human cases, 105 deaths, 40% CFR) led to the slaughter of over 1 million pigs. The virus was named after Sungai Nipah, the village where it was isolated from a fatal human case. Since then, nearly annual outbreaks have occurred in Bangladesh, and periodic outbreaks in India.

Virology & Pathophysiology

Nipah virus is a single-stranded, negative-sense RNA virus of the genus Henipavirus (family Paramyxoviridae). Two strains circulate in humans: NiV-Malaysia (NiV-M, isolated in 1999) and NiV-Bangladesh (NiV-B, endemic in Bangladesh since 2001) — the latter has a higher CFR and more documented human-to-human transmission. The genome encodes six major proteins; the fusion (F) and attachment (G) glycoproteins mediate cell entry through ephrin-B2 and ephrin-B3 — receptors expressed in neurons, brain endothelium, and respiratory epithelium.

Pathogenesis: NiV causes severe encephalitis (brain inflammation) as its primary manifestation. The virus infects brain endothelial cells and neurons, causing widespread vasculitis (blood vessel inflammation) and neuronal necrosis. This explains the acute neurological syndrome: altered consciousness, seizures, and rapid progression to coma. NiV also infects the respiratory tract, causing severe pneumonia — respiratory spread may explain some human-to-human transmission clusters, particularly in Bangladesh healthcare settings. The high CFR (40–75%) reflects the virus's neurotropism, high replication efficiency, and the lack of effective treatments.

Bat Reservoir & Transmission Routes

Pteropus fruit bats (flying foxes) are the natural reservoir for Nipah virus. These large bats roost in trees across South and Southeast Asia and are seropositive for NiV across their range (Bangladesh, India, Malaysia, Cambodia, Indonesia, Thailand). NiV is shed in bat urine, saliva, and fruit pulp. Human infection occurs via:

• Raw date palm sap (Bangladesh/India): Bats contaminate collection pots at night. Drinking fresh, unboiled date palm sap is the dominant route in Bangladesh outbreaks. Key prevention: using skirts/guards on collection pots to prevent bat access.
• Pig amplification (Malaysia 1998–99): Bats dropped partially eaten fruit into pig farms; pigs amplified the virus; pig farmers infected via close contact with sick pigs. No pigs in Bangladesh outbreaks.
• Direct bat contact: Climbing trees with bat roosting, handling bat carcasses, eating partly eaten fruit dropped by bats
• Human-to-human: Documented in Bangladesh and India through close household or healthcare contact with infected individuals. CFR in healthcare-acquired NiV cases similar to community cases. Droplet and direct contact transmission; N95 + contact precautions recommended for HCWs.
• Not food-borne beyond sap: NiV is unlikely to survive cooking; all documented cases are linked to uncooked/unboiled exposure or direct contact

Clinical Features & Management

Clinical Phases

• Prodrome (3–14 days incubation; then 3–5 days): Fever, headache, myalgia, vomiting — non-specific febrile illness
• Neurological phase: Rapidly progressive encephalitis — drowsiness, disorientation, seizures, altered consciousness progressing to coma within days
• Respiratory phase (NiV-B predominant): Atypical pneumonia, respiratory distress; may precede or accompany neurological features
• Relapsing encephalitis: Unique to NiV — encephalitis can relapse weeks to months after apparent recovery; caused by viral reactivation. Documented in Malaysian survivors.

Treatment

• No approved specific antiviral or vaccine for NiV in humans
• Ribavirin: Used empirically during Malaysian outbreak; observational data suggests possible benefit (reduced mortality in one study); not confirmed in RCT. Current WHO recommendation: ribavirin may be considered under compassionate use
• m102.4 (monoclonal antibody): Neutralizing antibody targeting NiV G protein; showed protection in animal models; used under compassionate use in Australia 2009; Phase I trials in humans completed — shows promise
• Supportive ICU care: Mechanical ventilation for respiratory failure; anticonvulsants for seizures; ICP management for raised intracranial pressure

Vaccine & Research Pipeline

Nipah is a WHO R&D Blueprint priority pathogen — recognized as one of the viruses most likely to cause a future epidemic or pandemic with no available countermeasures. Several vaccine candidates are in development:

• ChAdOx1 NiV (Oxford/AstraZeneca): Chimpanzee adenovirus vector expressing NiV G glycoprotein. Phase 1 trials ongoing. Shows strong immunogenicity in preclinical studies.
• mRNA-1215 (Moderna): mRNA vaccine candidate targeting NiV. Phase 1 trial completed 2024. High seroconversion rate; safety profile consistent with other mRNA vaccines.
• HeVsG subunit vaccine (CSIRO): Recombinant Hendra virus G protein vaccine already approved for horses; cross-reactive with NiV; human clinical trials in progress
• Favipiravir, remdesivir: Being evaluated against NiV in animal models with some promising results

Country-Specific Information

Frequently Asked Questions

Sources & Citations

Why Nipah Is a WHO Priority Pathogen

The WHO R&D Blueprint identifies Nipah as a priority pathogen for accelerated research and development due to:

• High CFR: 40–75% — among the highest of any known human pathogen
• Human-to-human transmission: Documented in healthcare settings; potential for sustained chains of transmission
• No approved vaccines or treatments: Supportive care only; very high mortality even with ICU care
• Pandemic potential: If NiV acquired efficient sustained human-to-human transmission (1–2 mutations may be sufficient based on research), its CFR would make it potentially more devastating than COVID-19 by orders of magnitude
• Wide bat reservoir range: Pteropus fruit bats range from Australia to South Asia — much wider than current human outbreak geography; introduction into new regions is possible
• Limited surveillance infrastructure: Most outbreaks occur in regions with limited health system capacity, potentially leading to delayed detection

Infection Control & Healthcare Worker Safety

Nipah virus in healthcare settings poses a high occupational hazard. Healthcare-associated transmission has been well-documented in Bangladesh, where nursing care of NiV patients has resulted in nosocomial outbreaks. Key IPC principles:

• Standard + Droplet + Contact precautions: Minimum precautions for confirmed or suspected NiV cases. N95 respirator or higher; gown; gloves; face shield for aerosol-generating procedures
• Airborne precautions: Full airborne precautions (PAPR or N95 in negative-pressure room) during intubation, bronchoscopy, suctioning, or CPR
• Single-room isolation: Preferred; negative-pressure room if available; minimize staff entering the room
• PPE donning/doffing training: Strict supervised donning and doffing protocols; the doffing process is highest-risk for contamination
• Visitor restriction: Essential visitors only; full PPE; contact tracing of all healthcare workers who had unprotected contact
• Laboratory: All NiV samples handled at minimum BSL-3; viral culture BSL-4. Inactivation before routine testing.

Nipah Survivor Outcomes & Relapsing Encephalitis

Nipah virus survivors face distinct long-term challenges:

• Relapsing encephalitis: A unique feature of NiV — encephalitis can recur weeks to years after apparent recovery. Documented in 7.5% of Malaysian outbreak survivors. Mechanism: viral persistence in CNS with reactivation. Clinical presentation: new neurological symptoms (seizures, personality changes, focal deficits) in a recovered patient.
• Late-onset encephalitis: Similar to relapsing form but occurring for the first time months after initial asymptomatic or mild acute infection. Documented in Malaysian survivors who had respiratory illness but no initial encephalitis.
• Neuropsychiatric sequelae: PTSD, depression, cognitive impairment (memory, attention), and fatigue are common in survivors
• Social stigma: Nipah survivors and their families face significant stigma in affected communities in Bangladesh and Kerala; community education is critical
• Long-term monitoring: WHO recommends ongoing neurological follow-up for NiV survivors given the risk of relapsing encephalitis; MRI and EEG monitoring protocols

Related Diseases

Key Terms: Nipah Virus

• NiV: Nipah virus — the causative Henipavirus of nipah encephalitis; two strains: NiV-Malaysia and NiV-Bangladesh
• Henipavirus: A genus of paramyxoviruses including Nipah and Hendra virus; named after Hendra in Queensland, Australia (Hendra) and Nipah village in Malaysia (Nipah)
• Pteropus fruit bat: Large fruit bat (flying fox) species across South and Southeast Asia; natural reservoir of Nipah virus; wingspans up to 1.5 meters
• Encephalitis: Inflammation of the brain — the primary manifestation of Nipah virus disease; causes fever, altered consciousness, seizures, and coma
• Date palm sap (khejurer rosh): Raw sap collected from date palm trees in Bangladesh and West Bengal; the primary human exposure route for Nipah virus when contaminated by bat urine overnight
• Relapsing encephalitis: A unique feature of NiV — neurological illness recurring weeks to months after apparent recovery; documented in Malaysian outbreak survivors
• NiV-B: Nipah virus Bangladesh strain — endemic in Bangladesh; higher documented human-to-human transmission rate; slightly higher CFR than NiV-M
• Ephrin receptors: The cell surface receptors (ephrin-B2 and ephrin-B3) used by Nipah virus for cell entry; expressed in neurons, brain endothelium, and respiratory epithelium — explaining NiV's neurotropism
• mAb m102.4: A neutralizing monoclonal antibody targeting the Nipah G glycoprotein; showed protection in animal models; used under compassionate use; Phase I trials completed
• CEPI: Coalition for Epidemic Preparedness Innovations — funds R&D for Nipah and other epidemic-risk pathogen vaccines including mRNA-1215 (Moderna NiV candidate)

More Nipah Questions

Epidemiology at a Glance: Nipah Virus

Nipah's limited geographic outbreak history reflects both its biological constraints (limited H2H transmission) and likely detection gaps in resource-limited settings.

Nipah Virus Prevention

• Bangladesh/India: Avoid raw date palm sap — Do not drink unboiled/unprocessed date palm sap (khejurer rosh). If collecting sap, use skirts or netting on collection pots to prevent bat access; boil sap before consumption. This single intervention addresses the majority of Bangladesh NiV cases.
• Avoid contact with fruit bats: Do not climb trees where Pteropus bats roost; do not handle bat carcasses; do not eat fruit that shows signs of bat nibbling or partial consumption
• Healthcare workers in outbreak settings: Full PPE (N95, gown, gloves, face shield) for any suspected NiV case; airborne precautions for aerosol-generating procedures; strict hand hygiene; limit staff entering isolation area
• If a NiV case is suspected: Immediately isolate the patient; notify public health authorities; trace all contacts (household and healthcare); initiate 21-day monitoring of contacts
• Surveillance: Any unexplained cluster of encephalitis with high mortality in South/Southeast Asia warrants NiV consideration. Contact the national public health institute for testing guidance.
• If traveling to Southeast Asia near bat habitats: Avoid caves with large bat populations; do not handle bats found on the ground; wash hands after outdoor activities in rural or forested areas

Nipah: Public Health Perspective